- Email: [email protected]
Summary of preclinical and early clinical experience with iodixanol
Summary of Preclinical and Early Clinical Experience with Iodixanol Edward L, Seigel, MD
I odixanol represents a new class of radiographic contrast agents, the isosmolar contrast media. The preceding articles assess the safety, efficacy, and tolerability of this new agent in comparison with iohexol, ioxaglate, iopromide, and iopamidol, all of which are low-osmolarity agents. The procedures carried out in these comparator trials included cerebral angiography, intracranial computed tomography (CT), body CT, extremity phlebography, aortography and renal/visceral angiography, peripheral arteriography, and excretory urography. The safely and efficacy of iodixanol were observed to be equivalent to that of comparator media across all procedures. The combination of isosmolality and low chemotoxicity probably accounts for the finding that patients who reacted previously to administration of contrast media have the same rate of adverse events after receiving iodixanol as do those who did not react previously. This relative risk of i compares to relative risk values of 2 for iohexol and 5 for ioxaglate. Work in progress indicates that similar results occur in patients with a history of congestive heart failure or with renal insufficiency, asthma, diabetes, hypertension, or vascular disease. Accordingly, iodLxanol appears to provide an extra margin of tolerability, especially in sensitive patients or in patients whose conditions are complicated by concurrent disease states. Additional trials will aid in further defining the role of iodixanol in clinical practice.
$528
I odixanol represents a new class of radiographic contrast agents, the isosmolar contrast media. The preceding articles assess the safety, efficacy, and tolerability of this new agent in comparison with iohexol, ioxaglate, iopromide, and iopamidol, all of which are low-osmolarity agents. The procedures carried out in these comparator trials included cerebral angiography, intracranial computed tomography (CT), body CT, extremity phlebography, aortography and renal/visceral angiography, peripheral arteriography, and excretory urography. The safely and efficacy of iodixanol were observed to be equivalent to that of comparator media across all procedures. The combination of isosmolality and low chemotoxicity probably accounts for the finding that patients who reacted previously to administration of contrast media have the same rate of adverse events after receiving iodixanol as do those who did not react previously. This relative risk of i compares to relative risk values of 2 for iohexol and 5 for ioxaglate. Work in progress indicates that similar results occur in patients with a history of congestive heart failure or with renal insufficiency, asthma, diabetes, hypertension, or vascular disease. Accordingly, iodLxanol appears to provide an extra margin of tolerability, especially in sensitive patients or in patients whose conditions are complicated by concurrent disease states. Additional trials will aid in further defining the role of iodixanol in clinical practice.
$528